Gilead Sciences Beats Earnings Forecasts, Sovaldi Sales Strong, Shares Slump

Everyone was expecting good things from Gilead Sciences (GILD). Gilead delivered, though not enough for investors. AP Gilead Sciences’ Hepatitis-C medication Sovaldi Gilead Sciences reported a profit of $2.36 a share, beating analyst forecasts for $1.79, on sales of $6.5 billion, easily topping the Street consensus for $5.9 billion. Gilead reported $3.48 billion in Sovaldi [...]